These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 37943779)

  • 41. [Comparative Study of PD-L1 Expression in Different Sites of 
Non-small Cell Lung Cancer].
    Huang X; Wu J; Zhou L; Song Z; Xu W; Jia L; Diao X; Wu Q; Lin D
    Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):303-310. PubMed ID: 35570146
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects.
    Bravaccini S; Bronte G; Petracci E; Puccetti M; D'Arcangelo M; Ravaioli S; Tumedei MM; Maltoni R; Delmonte A; Cappuzzo F; Crinò L
    Front Cell Dev Biol; 2021; 9():772216. PubMed ID: 34917615
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC.
    Gauvin C; Krishnan V; Kaci I; Tran-Thanh D; Bédard K; Albadine R; Leduc C; Gaboury L; Blais N; Tehfe M; Routy B; Florescu M
    Curr Oncol; 2021 Jan; 28(1):593-605. PubMed ID: 33498159
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials.
    Peng TR; Wu TW
    Thorac Cancer; 2019 May; 10(5):1176-1181. PubMed ID: 30969033
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer.
    Qin A; Lima F; Bell S; Kalemkerian GP; Schneider BJ; Ramnath N; Lew M; Krishnan S; Mohammed S; Rao A; Frankel TL
    Sci Rep; 2022 May; 12(1):9054. PubMed ID: 35641540
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series.
    Ishi A; Tanaka I; Iwama S; Sakakibara T; Mastui T; Kobayashi T; Hase T; Morise M; Sato M; Arima H; Hashimoto N
    Endocr J; 2021 May; 68(5):613-620. PubMed ID: 33790087
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.
    Zhong YM; Yin K; Chen Y; Xie Z; Lv ZY; Yang JJ; Yang XN; Zhou Q; Wang BC; Zhong WZ; Gao LL; Zhou WB; Chen J; Tu HY; Liao RQ; Zhang DK; Zhang SL; Lu DX; Zheng HB; Zhang HH; Wu YL; Zhang XC
    Front Immunol; 2022; 13():951817. PubMed ID: 36263036
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.
    Pérol M; Felip E; Dafni U; Polito L; Pal N; Tsourti Z; Ton TGN; Merritt D; Morris S; Stahel R; Peters S
    Ann Oncol; 2022 May; 33(5):511-521. PubMed ID: 35218887
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correction: Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness.
    Ruiz de Garibay G; Herranz C; Llorente A; Boni J; Serra-Musach J; Mateo F; Aguilar H; Gómez-Baldó L; Petit A; Vidal A; Climent F; Hernández-Losa J; Cordero Á; González-Suárez E; Sánchez-Mut JV; Esteller M; Llatjós R; Varela M; López JI; García N; Extremera AI; Gumà A; Ortega R; Plà MJ; Fernández A; Pernas S; Falo C; Morilla I; Campos M; Gil M; Román A; Molina-Molina M; Ussetti P; Laporta R; Valenzuela C; Ancochea J; Xaubet A; Casanova Á; Pujana MA
    PLoS One; 2018; 13(11):e0207586. PubMed ID: 30419005
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.
    Sheffield BS; Fulton R; Kalloger SE; Milne K; Geller G; Jones M; Jacquemont C; Zachara S; Zhao E; Pleasance E; Laskin J; Jones SJ; Marra MA; Yip S; Nelson BH; Gown AM; Ho C; Ionescu DN
    J Histochem Cytochem; 2016 Oct; 64(10):587-600. PubMed ID: 27591097
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correction: Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients.
    Sardaro A; Saito K; Nakayama E; Valmori D
    PLoS One; 2016; 11(7):e0160538. PubMed ID: 27467222
    [TBL] [Abstract][Full Text] [Related]  

  • 52. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
    Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
    Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
    Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A
    Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy.
    Wu F; Jiang T; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J; Bai X; Ren S; Zhou C;
    Cancer Commun (Lond); 2022 Dec; 42(12):1331-1346. PubMed ID: 36331328
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
    Luo W; Wang Z; Tian P; Li W
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC.
    Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y
    Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer: A meta-analysis.
    Wu LG; Zhou DN; Wang T; Ma JZ; Sui H; Deng WL
    Medicine (Baltimore); 2021 Mar; 100(12):e25145. PubMed ID: 33761681
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
    Barlesi F; Vansteenkiste J; Spigel D; Ishii H; Garassino M; de Marinis F; Özgüroğlu M; Szczesna A; Polychronis A; Uslu R; Krzakowski M; Lee JS; Calabrò L; Arén Frontera O; Ellers-Lenz B; Bajars M; Ruisi M; Park K
    Lancet Oncol; 2018 Nov; 19(11):1468-1479. PubMed ID: 30262187
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer.
    Jiang T; Liu H; Qiao M; Li X; Zhao C; Su C; Ren S; Zhou C
    Clin Lung Cancer; 2018 Mar; 19(2):e177-e184. PubMed ID: 29175386
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
    Li W; Jiang J; Huang L; Long F
    Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.